BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34414034)

  • 1. DOG1 is commonly expressed in pancreatic adenocarcinoma but unrelated to cancer aggressiveness.
    Jansen K; Büscheck F; Moeller K; Kluth M; Hube-Magg C; Blessin NC; Perez D; Izbicki J; Neipp M; Mofid H; Daniels T; Nahrstedt U; Fraune C; Jacobsen F; Bernreuther C; Lebok P; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Burandt E; Marx A; Krech T; Clauditz T
    PeerJ; 2021; 9():e11905. PubMed ID: 34414034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DOG1 expression is common in human tumors: A tissue microarray study on more than 15,000 tissue samples.
    Jansen K; Farahi N; Büscheck F; Lennartz M; Luebke AM; Burandt E; Menz A; Kluth M; Hube-Magg C; Hinsch A; Höflmayer D; Weidemann S; Fraune C; Möller K; Lebok P; Sauter G; Simon R; Uhlig R; Wilczak W; Jacobsen F; Minner S; Krech R; Clauditz T; Bernreuther C; Dum D; Krech T; Marx A; Steurer S
    Pathol Res Pract; 2021 Dec; 228():153663. PubMed ID: 34717148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucin 5AC expression is common but unrelated to tumor progression in pancreatic adenocarcinoma.
    Dwertmann Rico S; Büscheck F; Dum D; Luebke AM; Kluth M; Hube-Magg C; Hinsch A; Höflmayer D; Perez D; Izbicki JR; Neipp M; Mofid H; Daniels T; Isbert C; Fraune C; Möller K; Menz A; Bernreuther C; Lebok P; Clauditz T; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Burandt E; Marx A; Krech T
    Int J Immunopathol Pharmacol; 2022; 36():3946320221106504. PubMed ID: 35764407
    [No Abstract]   [Full Text] [Related]  

  • 4. Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness.
    Weidemann S; Perez D; Izbicki JR; Neipp M; Mofid H; Daniels T; Nahrstedt U; Jacobsen F; Bernreuther C; Simon R; Steurer S; Burandt E; Marx AH; Krech T; Clauditz TS; Jansen K
    Cancer Invest; 2021 Oct; 39(9):711-720. PubMed ID: 34143695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DOG1 overexpression is associated with mismatch repair deficiency and BRAF mutations but unrelated to cancer progression in colorectal cancer.
    Jansen K; Kluth M; Blessin NC; Hube-Magg C; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Burandt E; Perez D; Izbicki JR; Jacobsen F; Clauditz TS; Marx AH; Krech T
    Histol Histopathol; 2022 Aug; 37(8):739-748. PubMed ID: 35642329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DOG1 (clone K9) is seldom expressed and not useful in the evaluation of pancreatic neoplasms.
    Hemminger J; Marsh WL; Iwenofu OH; Frankel WL
    Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):397-401. PubMed ID: 22495382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic expression of DOG1: a novel gastrointestinal stromal tumor (GIST) biomarker.
    Ardeleanu C; Arsene D; Hinescu M; Andrei F; Gutu D; Luca L; Popescu LM
    Appl Immunohistochem Mol Morphol; 2009 Oct; 17(5):413-8. PubMed ID: 19417627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DOG1: a novel marker of salivary acinar and intercalated duct differentiation.
    Chênevert J; Duvvuri U; Chiosea S; Dacic S; Cieply K; Kim J; Shiwarski D; Seethala RR
    Mod Pathol; 2012 Jul; 25(7):919-29. PubMed ID: 22460810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases.
    Miettinen M; Wang ZF; Lasota J
    Am J Surg Pathol; 2009 Sep; 33(9):1401-8. PubMed ID: 19606013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors.
    Simon S; Grabellus F; Ferrera L; Galietta L; Schwindenhammer B; Mühlenberg T; Taeger G; Eilers G; Treckmann J; Breitenbuecher F; Schuler M; Taguchi T; Fletcher JA; Bauer S
    Cancer Res; 2013 Jun; 73(12):3661-70. PubMed ID: 23576565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional role of the Ca²⁺-activated Cl⁻ channel DOG1/TMEM16A in gastrointestinal stromal tumor cells.
    Berglund E; Akcakaya P; Berglund D; Karlsson F; Vukojević V; Lee L; Bogdanović D; Lui WO; Larsson C; Zedenius J; Fröbom R; Bränström R
    Exp Cell Res; 2014 Aug; 326(2):315-25. PubMed ID: 24825187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DOG1 for the diagnosis of gastrointestinal stromal tumor (GIST): Comparison between 2 different antibodies.
    Lopes LF; West RB; Bacchi LM; van de Rijn M; Bacchi CE
    Appl Immunohistochem Mol Morphol; 2010 Jul; 18(4):333-7. PubMed ID: 20571340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is DOG1 Immunoreactivity Specific to Gastrointestinal Stromal Tumor?
    Swalchick W; Shamekh R; Bui MM
    Cancer Control; 2015 Oct; 22(4):498-504. PubMed ID: 26678977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of discovered on gastrointestinal stromal tumor 1 (DOG1) antibody in surgical pathology-the GIST of it.
    Lee CH; Liang CW; Espinosa I
    Adv Anat Pathol; 2010 May; 17(3):222-32. PubMed ID: 20418677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DOG1 expression in neuroendocrine neoplasms: Potential applications and diagnostic pitfalls.
    Marando A; Di Blasi E; Tucci F; Aquilano MC; Bonoldi E
    Pathol Res Pract; 2023 Aug; 248():154623. PubMed ID: 37331184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical Inhibition of DOG1/TMEM16A Achieves Antitumoral Effects in Human Gastrointestinal Stromal Tumor Cells
    Fröbom R; Sellberg F; Xu C; Zhao A; Larsson C; Lui WO; Nilsson IL; Berglund E; Bränström R
    Anticancer Res; 2019 Jul; 39(7):3433-3442. PubMed ID: 31262867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes.
    Fraune C; Burandt E; Simon R; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Büscheck F; Höflmayer D; Blessin NC; Mandelkow T; Li W; Perez D; Izbicki JR; Wilczak W; Sauter G; Schrader J; Neipp M; Mofid H; Daniels T; Isbert C; Clauditz TS; Steurer S
    Ann Surg Oncol; 2020 Oct; 27(10):3997-4006. PubMed ID: 32108923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DOG1 as a novel antibody-drug conjugate target for the treatment of multiple gastrointestinal tumors and liver metastasis.
    Wu Y; Li W; Chen X; Wang H; Su S; Xu Y; Deng X; Yang T; Wei M; Li L; Liu Y; Yang J; Li W
    Front Immunol; 2023; 14():1051506. PubMed ID: 36776873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Novel Monoclonal Antibody Against DOG1 as a Diagnostic Marker for Gastrointestinal Stromal Tumors.
    Abdel-Hadi M; Bessa SS; Hamam SM
    J Egypt Natl Canc Inst; 2009 Sep; 21(3):237-47. PubMed ID: 21132034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DOG1 Expression in Low-Grade Fibromyxoid Sarcoma: A Study of 11 Cases, With Molecular Characterization.
    Thway K; Ng W; Benson C; Chapman J; Fisher C
    Int J Surg Pathol; 2015 Sep; 23(6):454-60. PubMed ID: 26135531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.